Study Identifies Benefits and Risks of GLP-1 Drugs Across 175 Health Outcomes

A recent study published in Nature Medicine may provide valuable insights into the previously unreported benefits and risks of glucagon-like peptide-1 (GLP-1) receptor agonist use on a set of 175 health outcomes.

Authors

Publication Details

Journal
JAMA
Published
2025-02-21
DOI
https://doi.org/10.1001/jama.2025.0542
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Study Identifies Benefits and Risks of GLP-1 Drugs Across 175 Health Outcomes

Samantha Anderer
JAMA
Diabetes Treatment and Management
article

Study Identifies Benefits and Risks of GLP-1 Drugs Across 175 Health Outcomes

Samantha Anderer
article en

Abstract

A recent study published in Nature Medicine may provide valuable insights into the previously unreported benefits and risks of glucagon-like peptide-1 (GLP-1) receptor agonist use on a set of 175 health outcomes.

JAMAVol. 333(12)
Openalex Percentile: Top 95%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Study Identifies Benefits and Risks of GLP-1 Drugs Across 175 Health Outcomes — Samantha Anderer · JAMA (2025) | TGRS Research Map | TGRS